Status:

COMPLETED

Coronary Artery Disease Severity in Newly Diagnosed Dysglycemia

Lead Sponsor:

Saud Al Babtain Cardiac Center

Conditions:

Coronary Artery Disease

Dysglycemia

Eligibility:

All Genders

18+ years

Brief Summary

This cohort study will measure how severe is the coronary artery disease (CAD), at time of CAD diagnosis, clinically and angiographically in the different cohorts of newly diagnosed diabetes and predi...

Eligibility Criteria

Inclusion

  • All adult patients with consents.
  • First time diagnosis of CAD and no prior diagnosis of diabetes milletus (DM), or prediabetes.
  • Coronary artery disease confirmed by invasive coronary angiography.

Exclusion

  • Patients with known significant anemia, increased hemoglobin turnover, active hemoglobin drops or on erythropoietin therapy.
  • Pregnant and post-partum patients (up to 3 months post-delivery).
  • Patients with severe chronic renal failure (estimated glomerular filtration rate (eGFR) \< 30 mL/min/1.72 m2).
  • Patients on any medications with glucose lowering effects.

Key Trial Info

Start Date :

July 1 2021

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

September 30 2022

Estimated Enrollment :

150 Patients enrolled

Trial Details

Trial ID

NCT05210972

Start Date

July 1 2021

End Date

September 30 2022

Last Update

October 26 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Saud Albatain cardiac Center

Dammam, Saudi Arabia